Comment

  • 19 June 2018

    EHA 2018: pivotal Phase III data for Daiichi Sankyo’s quizartinib

    Daiichi Sankyo’s pivotal data presentation at this year’s European Hematology Association (EHA) annual meeting showed that its FLT3 inhibitor quizartinib significantly improved patient outcomes in relapsed/refractory (R/R) FLT3-ITD-mutated acute myeloid...